(Q36196805)

12 August 2017

Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial (English)

1 reference

12 August 2017

0 references

Kai M Beeh

1

1 reference

12 August 2017

Dave Singh

series ordinal

2

1 reference

12 August 2017

Lilla Di Scala

series ordinal

3

1 reference

12 August 2017

Anton Drollmann

series ordinal

4

1 reference

12 August 2017

language of work or name

English

0 references

publication date

31 July 2012

1 reference

International Journal of Chronic Obstructive Pulmonary Disease

12 August 2017

1 reference

12 August 2017

7

1 reference

12 August 2017

503-513

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

12 August 2017

start time

1 July 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Scope, background and definition of pulmonary rehabilitation

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Strategies of muscle training in very severe COPD patients

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Sustained 24-h efficacy of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Pulmonary function and the risk of functional limitation in chronic obstructive pulmonary disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

The use of plethysmography and oscillometry to compare long-acting bronchodilators in patients with COPD.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

The clinical importance of dynamic lung hyperinflation in COPD.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

ATS/ACCP Statement on cardiopulmonary exercise testing

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

A randomised controlled comparison of tiotropium nd ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Impact of exercise capacity on dyspnea and health-related quality of life in patients with chronic obstructive pulmonary disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Safety and tolerability of NVA237, a once-daily long-acting muscarinic antagonist, in COPD patients

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Impact of changes in physical activity on health-related quality of life among patients with COPD.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Clinical relevance of constant power exercise duration changes in COPD.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Endurance shuttle walking test: responsiveness to salmeterol in COPD.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Minimal important difference of the transition dyspnoea index in a multinational clinical trial

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Dry powder ipratropium bromide is as safe and effective as metered-dose inhaler formulation: a cumulative dose-response study in chronic obstructive pulmonary disease patients

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3430121

Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms

22 September 2018

1 reference

12 December 2020

Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies

1 reference

12 December 2020

Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease

1 reference

12 December 2020

The major limitation to exercise performance in COPD is lower limb muscle dysfunction

1 reference

12 December 2020

The major limitation to exercise performance in COPD is dynamic hyperinflation

1 reference

12 December 2020

Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients

1 reference

12 December 2020

Acute administration of bronchodilators on exercise tolerance in treated COPD patients

1 reference

12 December 2020

Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD

1 reference

12 December 2020

Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD?

1 reference

12 December 2020

An Integrated Index Combined by Dynamic Hyperinflation and Exercise Capacity in the Prediction of Morbidity and Mortality in COPD

1 reference

12 December 2020

Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease

1 reference

12 December 2020

Identifiers

DOI

10.2147/COPD.S32451

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

22973092

1 reference